Capstone Holding Corp.
CAPS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.87M
Close$
Share Statistics
| Market cap | $2.87 Million |
|---|---|
| Enterprise Value | $20.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.12 |
| Beta | -1.48 |
| Outstanding Shares | 12,643,383 |
Return
| Return on Equity | -183.59% |
|---|---|
| Return on Assets | -41.70% |
| Return on Invested Capital | -37.04% |
Valuation & Multiples
| P/E Ratio | -0.05 |
|---|---|
| PEG | -0.05 |
| Price to Sales | 0.05 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.34 |
| Enterprise Value to EBIT | -2.01 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.87 |
| Debt to Equity | 1.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$0.12
Average shareholder expectationRevenue Estimate
$20.39 M
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$0.19
Average shareholder expectationRevenue Estimate
$24.60 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Capstone Holding Corp.
36 employees
CEO: Matthew E. Lipman Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its a...